In order to target tumor cells that overexpress the CXCR4 receptor, a CXCR4 ligand, DV3, was attached to TAT and two transducible anticancer peptides: A p53-activating peptide (DV3-TAT-p53C′) and a cyclin-dependent kinase 2 (Cdk2) antagonist peptide (DV3-TAT-RxL). The gene discussed is TP53; the disease is neoplasm.